Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIA 2-093 in Healthy Volunteers
NCT02171234Phase 1Completed
- Sponsor
- BIAL
- Start
- Feb 2001
- Primary completion
- Jun 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eslicarbazepine acetate in epilepsy (5 arms), sponsored by BIAL. Primary endpoint: Total Number of Adverse Events up to 20 weeks. Started Feb 2001; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02171234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171234.